Literature DB >> 11953333

Small therapeutic molecules for the treatment of inflammatory bowel disease.

S J H van Deventer1.   

Abstract

New therapies for inflammatory bowel disease are needed, because standard therapies fail to induce remission in about 30% of patients, and because of the relative inefficacy of current maintenance therapies. This review summarises the current status of the development of small therapeutic molecules for inflammatory bowel disease.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11953333      PMCID： PMC1867685          DOI： 10.1136/gut.50.suppl_3.iii47

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  135 in total

1.  p38MAP kinase is a negative regulator for ERK1/2-mediated growth of AIDS-associated Kaposi's sarcoma cells.

Authors:  K Murakami-Mori; S Mori; S Nakamura
Journal:  Biochem Biophys Res Commun       Date:  1999-11-02       Impact factor: 3.575

Review 2.  IkappaB-NF-kappaB structures: at the interface of inflammation control.

Authors:  P A Baeuerle
Journal:  Cell       Date:  1998-12-11       Impact factor: 41.582

3.  Results of a double blind study of the influence of thalidomide on the lepra reaction.

Authors:  J Sheskin; J Convit
Journal:  Int J Lepr Other Mycobact Dis       Date:  1969 Apr-Jun

4.  Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.

Authors:  R Eliakim; F Karmeli; E Razin; D Rachmilewitz
Journal:  Gastroenterology       Date:  1988-11       Impact factor: 22.682

5.  Constitutive and inducible in vivo protein-DNA interactions at the tumor necrosis factor-alpha promoter in primary human T lymphocytes.

Authors:  C Becker; K Barbulescu; S Wirtz; K H Meyer zum Büschenfelde; S Pettersson; M F Neurath
Journal:  Gene Expr       Date:  1999

6.  Further observation with thalidomide in lepra reactions.

Authors:  J Sheskin
Journal:  Lepr Rev       Date:  1965-10       Impact factor: 0.537

7.  Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B.

Authors:  T L Rowland; S M McHugh; J Deighton; P W Ewan; R J Dearman; I Kimber
Journal:  Int Immunopharmacol       Date:  2001-01       Impact factor: 4.932

8.  Effects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated by thrombin.

Authors:  L Rossignol; M Plantavid; H Chap; L Douste-Blazy
Journal:  Biochem Pharmacol       Date:  1988-09-01       Impact factor: 5.858

9.  Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor.

Authors:  D E Hammerschmidt; D Kotasek; T McCarthy; P W Huh; G Freyburger; G M Vercellotti
Journal:  J Lab Clin Med       Date:  1988-08

10.  Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis.

Authors:  J L Wallace
Journal:  Can J Physiol Pharmacol       Date:  1988-04       Impact factor: 2.273
View more
  5 in total

1.  Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution.

Authors:  Tomohisa Takagi; Yuji Naito; Kazuhiko Uchiyama; Toshimitsu Okuda; Katsura Mizushima; Takahiro Suzuki; Osamu Handa; Takeshi Ishikawa; Nobuaki Yagi; Satoshi Kokura; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2011-09-07       Impact factor: 5.742

2.  Osthole pretreatment alleviates TNBS-induced colitis in mice via both cAMP/PKA-dependent and independent pathways.

Authors:  Wu Sun; Yun Cai; Xin-Xin Zhang; Hao Chen; Yan-Die Lin; Hao Li
Journal:  Acta Pharmacol Sin       Date:  2017-06-12       Impact factor: 6.150

3.  Thalidomide induces mucosal healing in Crohn's disease: case report.

Authors:  Márcio Rios Leite; Sandra Sousa Santos; André Castro Lyra; Jaciane Mota; Genoile Oliveira Santana
Journal:  World J Gastroenterol       Date:  2011-12-07       Impact factor: 5.742

4.  Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells.

Authors:  T Kirkegaard; G Pedersen; T Saermark; J Brynskov
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

5.  Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.

Authors:  A Tannapfel; F Sommerer; M Benicke; A Katalinic; D Uhlmann; H Witzigmann; J Hauss; C Wittekind
Journal:  Gut       Date:  2003-05       Impact factor: 23.059
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.